# Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

> **NCT01950819** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2037 (actual)

## Conditions studied

- End Stage Renal Disease (ESRD)
- Chronic Kidney Disease (CKD)
- Hemodialysis
- Renal Replacement Therapy
- Renal Transplantation

## Interventions

- **BIOLOGICAL:** Induction therapy
- **DRUG:** Corticosteroids
- **DRUG:** EVR+rCNI
- **DRUG:** MPA+sCNI

## Key facts

- **NCT ID:** NCT01950819
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-03
- **Primary completion:** 2017-02-01
- **Final completion:** 2018-01-17
- **Target enrollment:** 2037 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01950819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01950819, "Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01950819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*